In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Walgreens Boots Alliance,
Inc. (NASDAQ:WBA), Altice USA, Inc. (NYSE:ATUS), Fortuna Silver
Mines Inc. (NYSE:FSM), Marathon Petroleum Corporation (NYSE:MPC),
Endologix, Inc. (NASDAQ:ELGX), and MYOS RENS Technology Inc.
(NASDAQ:MYOS), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified
analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
WBA DOWNLOAD: http://Capital-Review.com/register/?so=WBA
ATUS DOWNLOAD: http://Capital-Review.com/register/?so=ATUS FSM
DOWNLOAD: http://Capital-Review.com/register/?so=FSM MPC DOWNLOAD:
http://Capital-Review.com/register/?so=MPC ELGX DOWNLOAD:
http://Capital-Review.com/register/?so=ELGX MYOS DOWNLOAD:
http://Capital-Review.com/register/?so=MYOS
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Walgreens
Boots Alliance, Inc. (NASDAQ:WBA), Altice USA, Inc. (NYSE:ATUS),
Fortuna Silver Mines Inc. (NYSE:FSM), Marathon Petroleum
Corporation (NYSE:MPC), Endologix, Inc. (NASDAQ:ELGX), and MYOS
RENS Technology Inc. (NASDAQ:MYOS) on a fundamental level and
outlines the overall demand for their products and services in
addition to an in-depth review of the business strategy, management
discussion, and overall direction going forward. Several excerpts
from the recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
WALGREENS BOOTS ALLIANCE, INC. (WBA) REPORT
OVERVIEW
Walgreens Boots Alliance's Recent Financial
Performance
For the three months ended February 28th, 2019
vs February 28th, 2018, Walgreens Boots Alliance reported revenue
of $34,528.00MM vs $33,021.00MM (up 4.56%) and analysts estimated
basic earnings per share $1.25 vs $1.36 (down 8.09%). For the
twelve months ended August 31st, 2018 vs August 31st, 2017,
Walgreens Boots Alliance reported revenue of $131,537.00MM vs
$118,214.00MM (up 11.27%) and analysts estimated basic earnings per
share $5.07 vs $3.80 (up 33.42%). Analysts expect earnings to be
released on June 27th, 2019. The report will be for the fiscal
period ending May 31st, 2019. The reported EPS for the same quarter
last year was $1.53. The estimated EPS forecast for the next fiscal
year is $6.01 and is expected to report on October 10th, 2019.
To read the full Walgreens Boots Alliance, Inc. (WBA) report,
download it here:
http://Capital-Review.com/register/?so=WBA
-----------------------------------------
ALTICE USA, INC. (ATUS) REPORT OVERVIEW
Altice's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Altice reported revenue of $2,454.94MM vs
$2,359.81MM (up 4.03%) and analysts estimated basic earnings per
share $0.29 vs $3.26 (down 91.10%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Altice reported revenue
of $9,566.61MM vs $9,306.95MM (up 2.79%) and analysts estimated
basic earnings per share $0.03 vs $2.15 (down 98.60%). Analysts
expect earnings to be released on May 2nd, 2019. The report will be
for the fiscal period ending March 31st, 2019. Reported EPS for the
same quarter last year was -$0.16. The estimated EPS forecast for
the next fiscal year is $0.91 and is expected to report on February
20th, 2020.
To read the full Altice USA, Inc. (ATUS) report, download it
here:
http://Capital-Review.com/register/?so=ATUS
-----------------------------------------
FORTUNA SILVER MINES INC. (FSM) REPORT
OVERVIEW
Fortuna Silver Mines' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Fortuna Silver Mines reported revenue of
$59.59MM vs $75.35MM (down 20.92%) and analysts estimated basic
earnings per share $0.01 vs $0.22 (down 95.45%). For the twelve
months ended December 31st, 2018 vs December 31st, 2017, Fortuna
Silver Mines reported revenue of $263.30MM vs $268.11MM (down
1.80%) and analysts estimated basic earnings per share $0.21 vs
$0.42 (down 50.00%). Analysts expect earnings to be released on May
8th, 2019. The report will be for the fiscal period ending March
31st, 2019. Reported EPS for the same quarter last year was $0.09.
The estimated EPS forecast for the next fiscal year is $0.42 and is
expected to report on March 11th, 2020.
To read the full Fortuna Silver Mines Inc. (FSM) report,
download it here:
http://Capital-Review.com/register/?so=FSM
-----------------------------------------
MARATHON PETROLEUM CORPORATION (MPC) REPORT
OVERVIEW
Marathon Petroleum's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Marathon Petroleum reported revenue of
$32,333.00MM vs $21,055.00MM (up 53.56%) and basic earnings per
share $1.35 vs $3.97 (down 65.99%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Marathon Petroleum
reported revenue of $96,504.00MM vs $74,733.00MM (up 29.13%) and
analysts estimated basic earnings per share $5.36 vs $6.76 (down
20.71%). Analysts expect earnings to be released on May 8th, 2019.
The report will be for the fiscal period ending March 31st, 2019.
The reported EPS for the same quarter last year was $0.08. The
estimated EPS forecast for the next fiscal year is $9.09 and is
expected to report on February 6th, 2020.
To read the full Marathon Petroleum Corporation (MPC) report,
download it here:
http://Capital-Review.com/register/?so=MPC
-----------------------------------------
ENDOLOGIX, INC. (ELGX) REPORT OVERVIEW
Endologix's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Endologix reported revenue of $34.69MM vs
$44.00MM (down 21.16%) and analysts estimated basic earnings per
share -$2.67 vs -$1.67. For the twelve months ended December 31st,
2018 vs December 31st, 2017, Endologix reported revenue of
$156.47MM vs $181.16MM (down 13.63%) and analysts estimated basic
earnings per share -$9.07 vs -$7.97. Analysts expect earnings to be
released on May 1st, 2019. The report will be for the fiscal period
ending March 31st, 2019. The reported EPS for the same quarter last
year was -$1.60. The estimated EPS forecast for the next fiscal
year is -$4.12 and is expected to report on February 24th,
2020.
To read the full Endologix, Inc. (ELGX) report, download it
here:
http://Capital-Review.com/register/?so=ELGX
-----------------------------------------
MYOS RENS TECHNOLOGY INC. (MYOS) REPORT
OVERVIEW
MYOS RENS Technology's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, MYOS RENS Technology reported revenue of
$0.15MM vs $0.16MM (down 5.10%) and analysts estimated basic
earnings per share $0.00 vs -$0.17. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, MYOS RENS Technology
reported revenue of $0.36MM vs $0.53MM (down 31.56%) and analysts
estimated basic earnings per share -$0.45 vs -$0.69. Analysts
expect earnings to be released on May 8th, 2019. The report will be
for the fiscal period ending March 31st, 2019. The reported EPS for
the same quarter last year was -$0.19. The estimated EPS forecast
for the next fiscal year is -$0.54 and is expected to report on
March 26th, 2020.
To read the full MYOS RENS Technology Inc. (MYOS) report,
download it here:
http://Capital-Review.com/register/?so=MYOS
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jul 2023 to Jul 2024